Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Fate’s killer memory

How Fate is producing memory NK cells in its cancer candidate Fate-NK100

Fate Therapeutics Inc. has published the cell culture methodology behind Fate-NK100, its adoptive memory NK cell therapy in Phase I testing for cancer, and created two off-the-shelf versions of the candidate using iPS cells.

According to Jeffrey Miller, an academic collaborator on Fate’s NK cell programs, the key to Fate’s approach is its ability to isolate and expand subsets of NK cells with enhanced anticancer activity and prolonged lifespan in vivo compared with the general NK cell

Read the full 767 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers